Prognostic factors of juvenile myelomonocytic leukemia (JMML) have not been clarified because of its very low incidence and inaccuracy in the diagnosis. The purpose of this study was to evaluate children with JMML given an allogeneic hematopoietic stem cell transplantation (SCT) and the role of different variables potentially influencing outcome in a nationwide survey in Japan based on the newly proposed criteria by the International JMML Working Group. The study patients were 27 children who underwent SCT among 55 JMML patients retrospectively collected in the survey. The source of grafts was HLA-identical siblings in 12 cases, HLA-matched unrelated individuals in 10 and others in five. Total body irradiation was used in 18 cases. Event-free and overall survival (OS) at 4 years after SCT were 54.2 ± 11.2% (s.e.) and 57.9 ± 11.0% (s.e.), respectively. Six patients died of relapse and three of complications. Patients with abnormal karyotypes showed a significantly lower OS than those with normal karyotypes (P Ͻ 0.001). Patients below 1 year of age showed a significantly higher OS than those of 1 year of age or more (P = 0.02). Patients with grade 0-1 acute graft-versus-host disease (GVHD) or chronic GVHD had a more favorable OS than those without them, although they were not statistically significant (P Ͼ 0.05). Other variables studied were not associated with OS. A multivariate analysis of these factors yielded the abnormal karyotype as the only significant risk factor for lower OS (risk ratio: 11.0; 95% CI: 2.7-45.1). Leukemia (2002) 16, 645-649.
Introduction
Juvenile myelomonocytic leukemia (JMML) is a rare disorder which was previously reported as juvenile chronic leukemia or chronic myelomonocytic leukemia. 1, 2 Hasle et al 3 described that JMML accounted for 33% of all cases of MDS in children less than 15 years old and 3% of all hematologic malignancies. The incidence was reported to be 0.6 per million children per year. The clinical course is aggressive. Niemeyer et al 4 reported that the probability of survival at 10 years was 39% for patients who received bone marrow transplantation (BMT) and 6% for patients who did not receive it. Allogeneic BMT was frequently employed in this disease, [5] [6] [7] [8] [9] [10] [11] but interpretation of the results was difficult due to variability in conditioning regimens, type of donors, and pretransplant therapy. In addition, it was also complicated by the inaccur- acy of the diagnosis in the past: patients of other myelodysplastic disorders seemed to be included in JMML.
A consensus on the diagnosis of the disease was reached only recently. The French-American-British (FAB) and WHO collaborative study group categorized JMML as one of the diseases which shared characteristics of both myelodysplastic syndrome (MDS) and myeloproliferative disease. 12 In addition, the International JMML Working Group proposed diagnostic criteria, employing both clinical and laboratory features. 13 The criteria have been widely accepted, and now problems of JMML are discussed on a common basis. 2 We conducted a retrospective nationwide survey of children with MDS in Japan and identified patients with JMML employing the proposed criteria for diagnosis of JMML. In this article, we describe the outcome of 27 patients who received allogeneic stem cell transplantation (SCT).
Patients and methods

Patients
Patients suspected of having JMML were retrospectively registered with the MDS committee of the Japanese Society of Pediatric Hematology (JSPH).
14 In total, 78 children had been diagnosed as such from 36 institutions throughout Japan between 1990 and 1997. Of these 78 patients, 55 met the criteria proposed by the International JMML Working Group (Table 1) . 13 Twenty-seven of the 55 patients had been treated with allogeneic SCT and these patients were used in the analysis. All the 27 patients fulfilled the major criteria. The number of minor criteria met varied among the patients. In vitro abnormal colony formation, that is, hypersensitivity to GM-CSF or spontaneous colony formation was observed in 14 out of the 15 patients tested (Table 2) . Clinical and hematologic charac- Diagnosis of JMML: major criteria, all three are required; minor criteria, at least two of five are required. Abnormal colony formation: spontaneous colony or hypersensitivity to GM-CSF. Hgb, hemoglobin; HbF, fetal hemoglobin; Plts, platelets; WBC, white blood cells, AML Tx, AML-oriented therapy; LD-CA, low-dose cytosine arabinoside; 13-cis-RA, 13-cis-retinoic acid; NA, not available.
teristics at diagnosis are shown in Table 2 . Age at diagnosis ranged from 1 month to 14 years (median, 2 years). The maleto-female ratio was 2.9 (20/7). Karyotypic abnormalities were detected in six patients. No patient had clinical features of neurofibromatosis type 1.
Treatment before SCT
Treatment was planned in each institute (Table 2 ). In 11 cases, chemotherapy designed for acute myelogenous leukemia (AML) was employed prior to transplantation. The remaining patients were treated with various regimens. Splenectomy was done in two patients (Nos 5 and 17). The median interval between diagnosis and transplantation was 9 months ranging from 2 to 58 months. In patients who received grafts from HLA-identical siblings, the median interval was 5 months ranging from 4 to 28 months, and it was 10 months ranging from 2 to 58 months in those transplanted from other than siblings.
Transplantation procedures (Tables 3 and 4)
The source of grafts varied widely. An HLA-identical sibling was available in 12 cases, and an HLA-A, B, DRB1 matched unrelated donor, which was supplied from the Japanese Marrow Donor Program (JMDP), was used in 10 cases. An HLA- 
Statistical analysis
Information on the prognosis was available as of 31 August 1999. The median follow-up for 18 surviving patients was 26 months (3 to 67 months) after SCT. Event-free survival and overall survival (OS) were calculated by the Kaplan-Meier method and the difference was tested with the log-rank test. The Cox proportional hazards model was employed to assess the independent effects of risk factors on OS, where the selection of variables was stepwise. All calculations were performed by PC-SAS (SAS Institute, PC-SAS, version 6, 1996, Cary, NC, USA).
647 Table 3 Stem cell transplantation information 
Results
Outcome of patients who received allogeneic SCT
Graft failure occurred in one patient (No. 13) who received CD34-positive selection of the bone marrow cells of a 2-antigen mismatched family donor, followed by signs of disease recurrence. In the other 26 patients, the median time required to achieve a granulocyte count greater than 0.5 × 10 9 /l was 20 days ranging from 12 to 50 days. Two patients died early due to interstitial pneumonitis (No. 9) and veno-occlusive disease of the liver (No. 11) on days 38 and 32, respectively. In the remaining 24 patients, the median time to achieve a reticulocyte count greater than 1% was 21 days ranging from 10 to 58 days. There was another patient (No. 15) in whom the platelet count never exceeded 50 × 10 9 /l and the disease recurred later. In the remaining 23 patients, the median time to obtain self-sustaining platelet levels greater than 50 × 10 9 /l was 40 days ranging from 21 to 159 days.
For all the 27 children, event-free survival at 4 years after SCT was 54.2 ± 11.2% (s.e.) and OS was 57.9 ± 11.0% (s.e.) ( Figure 1 ). All but one patient survived without the disease. Grade II-IV acute GVHD was observed in 15 children while chronic GVHD was present in 10 patients (Table 4) . Eleven children experienced life-threatening or grade 3/4 transplantrelated complications such as sepsis, idiopathic pneumonitis, thrombotic microangiopathy, and veno-occlusive disease of the liver (Table 4) . Death due to the complications of SCT occurred in three cases while death due to relapse occurred in six cases (Table 4) .
Leukemia
Analysis of prognostic factors
We performed a univariate analysis for prognostic factors. Variables included age, sex, HbF level, leukocyte count, platelet count, karyotype, the interval between diagnosis and SCT, the use of AML-oriented chemotherapy, the type of donor, the use of TBI, the type of GVHD prophylaxis, the degree of acute GVHD and the presence of chronic GVHD. Patients with a normal karyotype had a significantly better outcome (P Ͻ 0.001, Figure 2) . Also, age at diagnosis was associated with OS: patients younger than 1 year had a significantly better OS (log-rank P = 0.02, Figure 3) . None of the other variables were significantly associated with OS. Patients with grade 0-I acute GVHD (P = 0.12) and with chronic GVHD tended to have a better OS (P = 0.10). Notably, five of six patients who relapsed had developed no sign of chronic GVHD (Table 4) .
A multivariate analysis on these factors yielded karyotype to be the only significant risk factor with a risk ratio of 11.0 (95% confidence interval: 2.7-45.1).
Discussion
Several studies showed the efficacy of allogeneic hematopoietic SCT for JMML. [5] [6] [7] [8] [9] [10] [11] However, the results concerning prognostic factors after SCT were not necessarily clear partly because of inaccuracy of the diagnosis. It was not until recently that the disease entity of JMML was established. Owing to international collaborative efforts, diagnostic criteria for JMML have become widely accepted. In this report, we applied the criteria raised by the International JMML Working Group to our patients who were suspected of having JMML. Among 78 patients retrospectively registered by physicians to the MDS committee of JSPH, 55 of them (70.5%) were compatible with the diagnostic criteria of JMML. The rest of the 23 patients were excluded because some lacked clinical features while others lacked laboratory data. In addition, some viral infections such as cytomegalovirus, EB virus, and HHV-6 present with clinical features similar to those of JMML 13 and such cases were excluded from the study subjects.
In the multivariate analysis of prognostic factors, the presence of karyotypic abnormalities including monosomy 7 remained as the only significant prognostic factor for SCT, leading to poor outcome. This is inconsistent with the result in a large series of patients (43 children) reported by Locatelli et al. 10 However, in their study, event-free survival for patients with monosomy 7 tended to be lower than that for patients without monosomy 7. In our study, four of six patients who relapsed had an abnormal karyotype. These observations suggest that patients with an abnormal karyotype show an aggressive course. Younger age was associated with a better outcome in a univariate analysis, but the association did not become statistically significant in the multivariate analysis. Age and karyotype were closely related. Since the number of patients was relatively small in this study, any definitive conclusion concerning the significance of karyotype may not be drawn. In addition, the results should be interpreted with reservation. There might be a selection bias as the data were retrospectively collected through a nationwide registry.
Locatelli et al 10 also claimed that patients who received busulfan had a better 5-year event-free survival (62%) than those given TBI (11%). In our study the outcome of patients who received TBI was comparable to that of patients receiving a non-TBI regimen. The role of TBI in SCT for JMML needs to be judged in the context of late toxicity such as growth failure, 
Figure 1
Event-free survival and overall survival after SCT for all the patients. gonadal and thyroid damage, and cataracts. 15, 16 Accordingly, the use of TBI should be avoided in very young children. Intensive chemotherapy designed for AML before SCT did not result in a better survival. On this point this study agreed with the result of Locatelli et al. 10 Splenectomy before SCT was performed in only two cases in this study. Therefore, we could not evaluate the role of splenectomy before SCT.
The development of chronic GVHD was associated with better survival, although the association was not statistically significant, possibly because of the small sample size. In fact,
Figure 3
Overall survival after SCT for patients who were diagnosed before and after 12 months of age.
among six patients who relapsed, five had no signs of chronic GVHD. It is likely that the graft-versus-leukemia effect played an important role in preventing relapse of the disease, as suggested by others.
8,10 Accordingly, we may well discontinue the use of immunosuppressive agents to induce graft-versusleukemia effects after prevention of acute GVHD with an appropriate regimen.
Our results showed that more than half of the patients could be potentially cured with allogeneic SCT. To our knowledge, it was one of the best results reported in the literature. It is of interest that there was no difference in the outcome between patients who received grafts from sibling donors and those from alternative donors. Since all the donors were supplied from the Japanese registry, this encouraging result might be caused by the genetic homogeneity of the Japanese population. However, Bunin et al 17 from North America, also reported a favorable outcome with event-free survival of 64% for alternative donor SCT. We conclude that SCT from carefully selected alternative donors is a safe and curative procedure for children with JMML.
